The department has several ongoing research projects.
- ACE Inhibitors for the Prevention of Fibrosis in IBD and the Role of TGFBeta1: For the first time, we've proven that Captopril, an ACE inhibitor used in the treatment of arterial hypertension, is effective in the prevention of fibrosis in an experimental model of IBD. We found that this affect comprises a depression of Angiotensin II and TGFBeta 1 that we determined through molecular biology tests, including tissue measurement of mRNA of TGFbeta1 by a semi-nested quantitative PCR. Similarly, in collaboration with physicians of Asaf HaRofeh Hospital, our team carried out a study on the prevention of liver fibrosis by Captopril.
- The Impact of Stress on Inflammatory Bowel Diseases: Using the rat model under acute and chronic stress, we studied different parameters of colitis and cytokines related to inflammation and fibrosis. The role of Substance P was investigated in this model of colitis.
- Glutamine and its Beneficial Effects in Experimental Colitis: Extensive studies were done on the effects of the AA Glutamine in the TNBS model of colitis in rats (cooperative study with Profs. Savion and Levy from Hadassah's School of Medicine). Different aspects of its effects were considered, including the role of antioxidants and the possible use of Glutamine enemas in Ulcerative Colitis patients.
- The Role of Mast Cells in the Development of Fibrosis in Inflammatory Bowel Disease: A collaborative study with Prof. Levy-Shafer from the School of Pharmacy in Ein Kerem. The research studied the influence of mast cell activation and depression in the activity of IBD, and the development of fibrosis, with in-vivo and in-vitro experiments. This research is in its final stage before publication.
- Clinical and Basic Research Studying GI Disorders in Diabetes [performed during the past few years]:
We've performed several studies related to GI disorders in diabetics - Intestinal Transit Disorders in different experimental models of diabetic rats, studying the role of Nitric Oxide; gastrointestinal disorders in a large diabetic population; the influence of prokinetic drugs for the prevention of hypoglycemic events in diabetic patients with gastroparesis.
- Studies on New Therapeutic Approaches in the Treatment of Proctologic Diseases: 1-Nitric Oxide, Botulinim Toxin and Capsaicine for Refractory Fisura Ani: Studies with manometric correlation in over 100 patients. 6) Capsaicine for the treatment of severe and chronic Pruritus Ani has provided positive results in 40 patients.
- Functional Gastrointestinal Disorders: such as irritable bowel syndrome, gastro esophageal reflux, dyspepsia and non-cardiac chest pain. The development of specialized instruments for the diagnosis of these disorders, and assessment of response to therapy. Treatment of these disorders through hypnosis.
- Biotechnology and New Advances in Digestive Endoscopy: we have been active partners in the development of new metallic esophageal and biliary stents, we are studying new approaches for the potentially clogging status of biliary stents, which are important in an early decision concerning the use of metallic or plastic stents.